Evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer - A retrospective multicenter trial with an accompanying translational project

Evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer - A retrospective multicenter trial with an accompanying translational project - STREAM-I

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032412

Enrollment

800

Registered

2023-08-11

Start date

2024-09-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C54.1

Interventions

Group 1: Adult patients who underwent cytoreductive surgery in European cancer centers for advanced endometrial cancer with peritoneal metastases (FIGO IV) or for recurrent endometrial cancer.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients =18 years undergoing cytoreductive surgery for endometrial cancer between 01/2011 and 12/2020 with the following criteria: - Primary diagnosis of advanced endometrial cancer and peritoneal metastases (FIGO IV) undergoing cytoreductive surgery OR - Diagnosis of recurrent endometrial cancer undergoing cytoreductive surgery Optional but strongly encouraged for translational part: availability of FFPE tumor material from cytoreductive surgery

Exclusion criteria

Exclusion criteria: 1. Patients with past medical history interfering with radical cytoreductive surgery 2. Patients undergoing surgery solely for palliative intent 3. Patients with secondary

Design outcomes

Primary

Measure	Time frame
Identification of clinical selection criteria to predict complete cytoreduction in patients with advanced or recurrent endometrial cancer	—

Secondary

Measure	Time frame
Clinical part: - Evaluation of prognostic factors predicting benefit from cytoreductive surgery in advanced or recurrent endometrial cancer - Identification of prognostic markers for the clinical outcome Translational part: - Evaluating the predictive value of the molecular classification according to TCGA for surgical outcome in endometrial cancer - Identification of biologic and molecular expression profiles to predict complete cytoreduction in patients with endometrial cancer and their prognostic significance Exploratory objectives: - Description of current treatment practices in participating European countries for advanced or recurrent endometrial cancer	—

Measure

Time frame

Clinical part: - Evaluation of prognostic factors predicting benefit from cytoreductive surgery in advanced or recurrent endometrial cancer - Identification of prognostic markers for the clinical outcome Translational part: - Evaluating the predictive value of the molecular classification according to TCGA for surgical outcome in endometrial cancer - Identification of biologic and molecular expression profiles to predict complete cytoreduction in patients with endometrial cancer and their prognostic significance Exploratory objectives: - Description of current treatment practices in participating European countries for advanced or recurrent endometrial cancer

—

Countries

Austria, Belgium, Czechia, France, Germany, Israel, Italy, Switzerland, United Kingdom

Contacts

Public ContactOliver Adam

AGO Research GmbH

oadam@ago-ovar.de+4920195981216

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026